Coping with COVID vaccine concerns

Dr Linda Calabresi

writer

Dr Linda Calabresi

GP; Medical Editor, Healthed

Dr Linda Calabresi

Vaccine hesitancy is one thing, but a complete crisis of confidence is another. The AstraZeneca COVID vaccine, once touted as our get-out-of-jail-free card is now being viewed with suspicion and trepidation by an increasing number of our patients, according to a recent Healthed survey of GPs.

The survey of over 600 Australian GPs sought to gauge the public’s reaction to the AstraZeneca vaccine, following reports of the rare but headline-grabbing clotting side-effect.

Almost two-thirds of the GPs (64.72%) said they had seen an increase in the number of patients expressing serious concerns with regard the vaccine but would have it anyway. Even more worrying was the 60.53% who had more patients put off the vaccine until a later date because of very serious concerns, and 45.56% who had an increased number of patients refuse the vaccine completely.

And it would seem that even health professionals have some reservations with 64.7% saying, given the choice they would opt for the Pfizer one. However, a decent percentage (28.41%) said they didn’t mind whichever vaccine they were given while only 6.89% reported a preference for the AstraZeneca formulation.

 

If hypothetically, you could choose which vaccine you received, which would you prefer?

In your practice over the past 1-2 months, in what ways have the number of patients in each category changed?

  • Answered: 658
  • Skipped: 206

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Upcoming Healthed Webcast

New Brain Health Guidelines – What GPs Can Do

Tuesday 4th August, 7pm - 9pm AEST

Speaker

Scientia Prof Kaarin Anstey

Psychologist; Director, UNSW Ageing Futures Institute; ARC Laureate Fellow; Senior Principal Research Scientist, NeuRA

Scientia Prof Kaarin Anstey translates the WHO's updated 2026 dementia risk-reduction guidelines changes into concrete actions for opportunistic risk assessment and targeted advice in everyday general practice.